IRIS
VALENTINI, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 23.952
NA - Nord America 7.733
AS - Asia 5.885
SA - Sud America 1.240
AF - Africa 82
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 5
Totale 38.915
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 9.710
IT - Italia 7.897
US - Stati Uniti d'America 7.552
SG - Singapore 2.186
IE - Irlanda 1.852
CN - Cina 1.241
UA - Ucraina 1.124
BR - Brasile 1.075
HK - Hong Kong 1.035
GB - Regno Unito 850
DE - Germania 628
FR - Francia 582
VN - Vietnam 531
FI - Finlandia 320
NL - Olanda 273
SE - Svezia 253
TR - Turchia 220
GR - Grecia 198
IN - India 167
KR - Corea 157
CA - Canada 112
JP - Giappone 78
BE - Belgio 71
AR - Argentina 57
ES - Italia 48
ID - Indonesia 47
BD - Bangladesh 40
MX - Messico 39
IQ - Iraq 34
EC - Ecuador 32
PL - Polonia 31
CH - Svizzera 29
AT - Austria 26
ZA - Sudafrica 25
CO - Colombia 20
PK - Pakistan 17
UZ - Uzbekistan 17
PY - Paraguay 16
VE - Venezuela 14
TH - Thailandia 13
EG - Egitto 12
EU - Europa 12
MA - Marocco 12
RO - Romania 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
TW - Taiwan 10
CZ - Repubblica Ceca 9
HR - Croazia 9
KZ - Kazakistan 9
UY - Uruguay 9
HU - Ungheria 8
KE - Kenya 8
TN - Tunisia 8
AZ - Azerbaigian 6
CR - Costa Rica 6
PE - Perù 6
PH - Filippine 6
BH - Bahrain 5
BY - Bielorussia 5
DZ - Algeria 5
IR - Iran 5
JO - Giordania 5
NP - Nepal 5
AU - Australia 4
IL - Israele 4
KG - Kirghizistan 4
MY - Malesia 4
PA - Panama 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
ET - Etiopia 3
JM - Giamaica 3
LK - Sri Lanka 3
NI - Nicaragua 3
OM - Oman 3
RS - Serbia 3
SN - Senegal 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
DK - Danimarca 2
GT - Guatemala 2
HN - Honduras 2
LB - Libano 2
LT - Lituania 2
MK - Macedonia 2
MN - Mongolia 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
Totale 38.904
Salva come PNG Salva come JPEG
Città #
Moscow 3.441
Dublin 1.844
Jacksonville 1.576
Hong Kong 1.029
Santa Clara 816
Singapore 806
Chandler 756
Rome 520
San Jose 464
Milan 437
Ashburn 371
Princeton 288
Medford 254
Beijing 214
Ho Chi Minh City 203
Naples 171
Ann Arbor 166
Napoli 156
San Mateo 152
Seoul 152
Boardman 148
Roxbury 148
Wilmington 138
Hefei 126
Hanoi 123
Bremen 113
Woodbridge 113
Bengaluru 100
Palermo 91
Turin 91
Florence 89
Cambridge 83
Dallas 75
São Paulo 70
Catania 66
Des Moines 65
Mountain View 64
Brussels 62
Bari 61
Bologna 61
Caserta 58
Helsinki 58
The Dalles 55
Ottawa 52
Padova 50
Nanjing 49
New York 45
Verona 39
Genoa 34
Munich 33
Da Nang 31
Rio de Janeiro 31
Los Angeles 28
Torino 27
Brasília 26
Cagliari 26
Belo Horizonte 25
Messina 24
Taranto 24
Venice 24
Vicenza 24
Mcallen 23
Orem 23
Pescara 23
Toronto 22
Houston 21
Jinan 21
Nuremberg 21
Redwood City 21
Brescia 20
Guangzhou 20
Livorno 20
Parma 20
Frankfurt am Main 19
Haiphong 19
Modena 19
France 18
Genova 18
London 18
Perugia 18
Atlanta 17
Baghdad 17
Düsseldorf 17
Kunming 17
Norwalk 17
Salerno 17
Trieste 17
Reggio Emilia 16
Tokyo 16
Changsha 15
Curitiba 15
Gorno 15
Trento 15
Auburn Hills 14
Mumbai 14
Reggio Calabria 14
Tashkent 14
Campinas 13
Chicago 13
Falls Church 13
Totale 17.156
Salva come PNG Salva come JPEG
Nome #
ARTRITE PSORIASICA ED INTERSTIZIOPATIA POLMONARE : DESCRIZIONE DI UN CASO CLINICO. 8.338
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group 444
ANTI TNF ALFA IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE E SPONDILOARTRITI HBV CARRIERS OCCULTI:STUDIO RETROSPETTIVO SULLA SICUREZZA 301
A PILOT STUDY ON LOW-DOSE INTRAVENOUS CICLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS: EFFICACY, SAFETY AND EFFECTS ON CELLULAR ACTIVATION MARKERS 209
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 204
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 196
Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes 186
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 181
ANTI-TNFα TREATMENT IS ASSOCIATED WITH INCREASED LIVER STIFFNESS IN HBV OCCULT CARRIER PATIENTS 180
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 165
[T-lymphocyte subpopulations in the conjunctiva of subjects with secondary Sjogren's syndrome] 163
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis] 161
[HAQ-DI Italian version in systemic sclerosis]. 159
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 153
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 153
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 153
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 151
Alterazione del riempimento ventricolare sinistro nella sclerosi sistemica (SSc): risultati di uno studio Iongitudinale 150
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 150
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 148
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 147
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis 146
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 144
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 144
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY 143
ARTHRITIS IS ASSOCIATED WITH PSORIASIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES 143
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 142
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report] 141
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 139
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 138
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 138
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 138
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]. 137
[Hypocomplementemia in systemic sclerosis]. 137
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 137
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 136
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 136
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 136
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation 135
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma] 135
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS 133
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study]. 132
Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease 132
A SCLERODERMA PATIENT WITH SWOLLEN AND TENDER JOINTS OF BOTH HANDS 132
Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause 131
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 130
Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis 130
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 130
Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography 128
ANTI-TOPOISOMERASE I (ANTI-SCL-70) AND CANCER IN SYSTEMIC SCLEROSIS. ARE THEY RELATED? 127
Cardiac involvement in rheumatoid arthritis: an echocardiographic study 126
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative 126
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. 125
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 125
Evidence for peripheral impaired glucose handling in patients with connective tissue diseases 124
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database 123
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 123
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 123
ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. 123
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 123
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 122
New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. 122
Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. 122
[Rarity of sclerodermic renal crisis in the Italian population and the uncommon nature of the Vogt-Koyanagi-Harada syndrome in systemic sclerosis] 122
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 122
RELAPSING POLYCHONDRITIS. AN HYSTOCHEMICAL STUDY BY LECTIN. 121
.Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. 121
Alterazioni del sistema nervoso autonomo nella Sclerosi Sistemica (SSc). Risultati preliminari di uno studio sul rapporto con la severita della malattia 120
[Metabolic syndrome in inflammatory rheumatic diseases]. 120
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. 119
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients 119
Impaired exercise performance in systemic sclerosis and its clinical correlations 119
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 118
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 117
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 117
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 117
Brief report: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study. 117
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. 117
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 116
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 116
Crioglobulinemia mista essenziale: prevalenza e caratteri della neuropatia periferica 115
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 115
RELATIONSHIP OF THE 6-MIN WALKING TEST AND QUALITY OF LIFE 115
[The arthropathy of systemic sclerosis]. 114
Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature. 114
ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS: EVALUATION OF INTIMA-MEDIA THICKNESS AND CORRELATION WITH INFLAMMATORY AND ATHEROGENIC MARKERS 114
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 114
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 114
Cell-free DNA in the plasma of patients with systemic sclerosis 113
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 113
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group 113
Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review 113
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 112
Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases 112
Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries 111
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve 111
Systemic sclerosis 111
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study 110
[Early systemic sclerosis: diagnostic criteria and work-up]. 110
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy 109
Totale 21.920
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.202
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.202
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021822 0 0 0 0 0 0 0 0 0 363 312 147
2021/20222.634 245 77 93 103 738 103 106 162 134 120 201 552
2022/20234.527 430 195 113 303 394 316 112 297 1.767 184 204 212
2023/20242.785 195 131 182 285 626 109 189 230 130 161 228 319
2024/20255.492 125 162 120 195 715 859 820 459 612 803 381 241
2025/202615.629 526 591 852 893 1.372 9.137 815 518 686 239 0 0
Totale 39.512